Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease where the body’s natural defenses, like antibodies, attack the covering of the nerves, called myelin, and damage nerve function. While symptoms aren’t the same for everyone, CIDP can make your arms and legs feel weak and slow your movements. The purpose of the ARISE Study is …
Do you have numbness and tingling or pain in your feet from diabetes? Do you have pain after shingles (postherpetic pain)? The Translational Pain Research Group at the Brigham and Women’s Hospital in Boston, Massachusetts, is seeking volunteers who have diabetic nerve pain or pain following shingles to participate in a research study. Volunteers who …
RxFunction’s walk2wellness study has added Johns Hopkins in Baltimore Maryland as its fifth site for its ongoing clinical trial of its Walkasins Lower Limb Sensory Neuroprosthesis. The study is designed to assess Walkasins’ use on peripheral neuropathy patients at high-fall risk. Patients may now enroll at Johns Hopkins in Baltimore, as well as other study …
RxFunction’s walk2Wellness Study Adds a New Site Read More »
Erchonia Corporation is currently recruiting for a study on the effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy pain. This study can be found at ClinicalTrials.gov here. PURPOSE OF THE STUDY In this study, the Sponsor, Erchonia Corporation, and investigators are studying the use of a device called the Erchonia® FX-635™ that gives …
by Shanna Patterson, MD Around the New Year many people think about resolutions. For those of us contemplating how we can be our healthiest selves, this often includes recommitting to a healthy diet and exercise. Interestingly though it’s common to associate peripheral neuropathy with elevated blood sugar and diabetes, many may not be aware that …
The Foundation for Peripheral Neuropathy (FPN) is pleased to announce a new partnership to further research on anti-MAG IgM paraprotein-associated peripheral neuropathy. FPN will be partnering with the IMAGiNe study, a global research collaborative focusing on anti-MAG and IgM paraprotein-associated peripheral neuropathy. Thanks to a donation from the Atlantic Philanthropies Director/Employee Designated Gift Fund, FPN …
NeuroNEXT and the National Institute of Neurological Disorders and Stroke (NINDS) are undergoing a double-blind, placebo clinical trial looking at the effectiveness of treating peripheral neuropathy with the FDA-approved drug, topiramate. This is a 96-week placebo-controlled trial of topiramate at a target dose of 100 mg daily (50 mg twice daily) as a potentially disease …
Topiramate as a Disease Altering Therapy for Cryptogenic Sensory Peripheral Neuropathy Read More »
Northwestern University is conducting a Phase III clinical trial with Viromed Pharmaceuticals for an investigational drug (VM202) on painful, diabetic peripheral neuropathy in the legs and feet. This drug has been shown to be safe and effective at reducing pain caused by neuropathy through the generation of new blood vessels and nerves. The basic inclusion/exclusion …
Clinical Trial for Diabetic Peripheral Neuropathy Read More »
A common cause of neuropathy is diabetes, but in about 25 to 50% of the population no cause is found. This group is often referred to as cryptogenic sensory polyneuropathy (CSPN). This study looks at four different drugs in patients with CSPN and plan to determine which drug is most effective: nortriptyline, duloxetine, pregabalin, or mexiletine. …
Comparison of treatment in real life situations (pain controls) Read More »
